These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9435855)

  • 1. Diabodies: small bispecific antibody fragments.
    Holliger P; Winter G
    Cancer Immunol Immunother; 1997; 45(3-4):128-30. PubMed ID: 9435855
    [No Abstract]   [Full Text] [Related]  

  • 2. Boehringer splashes out on bispecific antibody platforms.
    Moran N
    Nat Biotechnol; 2011 Jan; 29(1):5-6. PubMed ID: 21221079
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
    Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
    Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A revival of bispecific antibodies.
    Kufer P; Lutterbüse R; Baeuerle PA
    Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
    [No Abstract]   [Full Text] [Related]  

  • 7. [Dual-specificity therapeutic antibodies].
    Winckler T
    Pharm Unserer Zeit; 2009; 38(5):395-6. PubMed ID: 19711313
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.
    Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB
    Int Immunol; 1998 Dec; 10(12):1863-72. PubMed ID: 9885907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering antibodies for therapy.
    Presta LG
    Curr Pharm Biotechnol; 2002 Sep; 3(3):237-56. PubMed ID: 12164480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells.
    Olafsen T; Rasmussen IB; Norderhaug L; Bruland OS; Sandlie I
    Immunotechnology; 1998 Oct; 4(2):141-53. PubMed ID: 9853955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
    Todorovska A; Roovers RC; Dolezal O; Kortt AA; Hoogenboom HR; Hudson PJ
    J Immunol Methods; 2001 Feb; 248(1-2):47-66. PubMed ID: 11223068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunology. Two-in-one designer antibodies.
    Parren PW; Burton DR
    Science; 2009 Mar; 323(5921):1567-8. PubMed ID: 19299606
    [No Abstract]   [Full Text] [Related]  

  • 13. Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats.
    Miller A; Carr S; Rabbitts T; Ali H
    MAbs; 2020; 12(1):1752529. PubMed ID: 32316838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New protein engineering approaches to multivalent and bispecific antibody fragments.
    Plückthun A; Pack P
    Immunotechnology; 1997 Jun; 3(2):83-105. PubMed ID: 9237094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the production of bispecific antibody fragments for clinical applications.
    Carter P; Ridgway J; Zhu Z
    J Hematother; 1995 Oct; 4(5):463-70. PubMed ID: 8581386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards an immunotherapy for p185HER2 overexpressing tumors.
    Carter P; Rodrigues ML; Lewis GD; Figari I; Shalaby MR
    Adv Exp Med Biol; 1994; 353():83-94. PubMed ID: 7985544
    [No Abstract]   [Full Text] [Related]  

  • 17. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
    Moore GL; Bautista C; Pong E; Nguyen DH; Jacinto J; Eivazi A; Muchhal US; Karki S; Chu SY; Lazar GA
    MAbs; 2011; 3(6):546-57. PubMed ID: 22123055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528.
    Asano R; Sone Y; Ikoma K; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
    Protein Eng Des Sel; 2008 Oct; 21(10):597-603. PubMed ID: 18621782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody fragments for controlled delivery of therapeutic agents.
    Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
    Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.